627 related articles for article (PubMed ID: 32500819)
1. Circulating tumour cells as prognosis predictive markers of neoadjuvant chemotherapy-treated breast cancer patients.
Cui Z; Su F; Li Y; Yang D
J Chemother; 2020 Oct; 32(6):304-309. PubMed ID: 32500819
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Pierga JY; Bidard FC; Autret A; Petit T; Andre F; Dalenc F; Levy C; Ferrero JM; Romieu G; Bonneterre J; Lerebours F; Bachelot T; Kerbrat P; Campone M; Eymard JC; Mouret-Reynier MA; Gligorov J; Hardy-Bessard AC; Lortholary A; Soulie P; Boher JM; Proudhon C; Charafe-Jaufret E; Lemonnier J; Bertucci F; Viens P
Ann Oncol; 2017 Jan; 28(1):103-109. PubMed ID: 28177480
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.
O'Toole SA; Spillane C; Huang Y; Fitzgerald MC; Ffrench B; Mohamed B; Ward M; Gallagher M; Kelly T; O'Brien C; Ruttle C; Bogdanska A; Martin C; Mullen D; Connolly E; McGarrigle SA; Kennedy J; O'Leary JJ
Breast Cancer Res Treat; 2020 Jun; 181(3):571-580. PubMed ID: 32378053
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Rack B; Schindlbeck C; Jückstock J; Andergassen U; Hepp P; Zwingers T; Friedl TW; Lorenz R; Tesch H; Fasching PA; Fehm T; Schneeweiss A; Lichtenegger W; Beckmann MW; Friese K; Pantel K; Janni W;
J Natl Cancer Inst; 2014 May; 106(5):. PubMed ID: 24832787
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of Circulating Tumor Cells for Evaluating Short- and Long-Term Efficacy of Chemotherapy for Breast Cancer.
Ma S; Ling F; Gui A; Chen S; Sun Y; Li Z
Med Sci Monit; 2017 Oct; 23():4808-4816. PubMed ID: 28986517
[TBL] [Abstract][Full Text] [Related]
7. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Bidard FC; Mathiot C; Delaloge S; Brain E; Giachetti S; de Cremoux P; Marty M; Pierga JY
Ann Oncol; 2010 Apr; 21(4):729-733. PubMed ID: 19850639
[TBL] [Abstract][Full Text] [Related]
8. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Riethdorf S; Müller V; Zhang L; Rau T; Loibl S; Komor M; Roller M; Huober J; Fehm T; Schrader I; Hilfrich J; Holms F; Tesch H; Eidtmann H; Untch M; von Minckwitz G; Pantel K
Clin Cancer Res; 2010 May; 16(9):2634-45. PubMed ID: 20406831
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of neoadjuvant chemotherapy and Annexin A3 expression in breast cancer.
Zhu S; Li Y; Wang Y; Cao J; Li X; Wang J; Wang X
J BUON; 2019; 24(2):522-528. PubMed ID: 31128000
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
12. Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Hepp P; Andergassen U; Jäger B; Trapp E; Alunni-Fabbroni M; Friedl TW; Hecker N; Lorenz R; Fasching P; Schneeweiss A; Fehm T; Janni W; Rack B
Anticancer Res; 2016 Sep; 36(9):4771-6. PubMed ID: 27630326
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
14. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer.
Ni C; Shen Y; Fang Q; Zhang M; Yuan H; Zhang J; Zhong M; Zheng Y
Cancer Med; 2020 Apr; 9(7):2290-2298. PubMed ID: 32017443
[TBL] [Abstract][Full Text] [Related]
16. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.
Taucher S; Rudas M; Mader RM; Gnant M; Sporn E; Dubsky P; Roka S; Bachleitner T; Fitzal F; Kandioler D; Wenzel C; Steger GG; Mittlböck M; Jakesz R
Breast Cancer Res Treat; 2003 Dec; 82(3):207-13. PubMed ID: 14703068
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Imai A; Okamoto A; Hamaoka A; Soushi M; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Goto M; Yamada K; Taguchi T
Breast Cancer; 2017 Jan; 24(1):92-97. PubMed ID: 26874836
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
